US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.41 against a street estimate of -0.42 — a beat of 2.4%.
Analysts rate Aytu BioScience Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $9.50.
| Fund | Stake |
|---|---|
| Nantahala Capital Management, LLC | 10.13% |
| Stonepine Capital Management Llc | 7.38% |
| Awm Investment Company Inc | 5.77% |
| Vanguard Capital Management, LLC | 2.43% |
| CROWN ADVISORS MANAGEMENT, INC. | 1.86% |
| Diadema Partners LP | 1.38% |
| Two Sigma Investments LLC | 0.98% |
| Renaissance Technologies Corp | 0.87% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aytu BioScience Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.